StacksVerified U.S. regulatory reference

Part 316 — Orphan Drugs

Subpart A — General Provisions

Subpart B — Written Recommendations for Investigations of Orphan Drugs

Subpart C — Designation of an Orphan Drug

Subpart D — Orphan-drug Exclusive Approval

Subpart E — Open Protocols for Investigations

Subpart F — Availability of Information